Significant Strategic Marketing Agreement with Leading Global Drug Delivery and Outsourcing Provider
The Medical House PLC ("TMH" or the "Company") (AIM:MLH), the drug delivery specialist, is pleased to announce that it has today signed a strategic marketing agreement with Catalent Pharma Solutions ("Catalent"), one of the leading global providers of advanced technologies and outsourcing services (formerly the Pharmaceutical Technologies and Services segment of Cardinal Health, Inc).
Under the terms of this agreement, the companies will jointly promote and market TMH's "ASI" disposable AutoSafety Injector system in combination with Catalent's services and technologies, which include sterile filling of pre-filled syringes. Catalent offers extensive capabilities for the development, manufacture and packaging of pharmaceutical and biotechnology products, and brings to the collaboration extensive customer relationships in nearly 100 countries, and an experienced business development team operating in the world's leading pharmaceutical markets.
The companies are also exploring opportunities to jointly develop specific drug & device combination products, which if successful may be suitable for out-licensing and/or marketing partnerships with pharmaceutical industry partners.
Richard Yarwood, Group President of Catalent's Sterile Technologies segment, said, "We believe that the ASI autoinjector system provides pharmaceutical companies with an easy to use, cost-effective and patient-friendly alternative which enhances and complements the range of technologies and services which Catalent can provide. We are confident that this collaboration will be beneficial for The Medical House, Catalent and our customers. "
Ian Townsend Chairman of TMH commented, "We are delighted to have signed this agreement which will significantly raise the profile of our ASI technology within the pharmaceutical industry. We fully expect that this relationship with such a major player will provide significant new business opportunities for the ASI. Given Catalent's key role and involvement in pharmaceutical and biotechnology companies' drug development programmes, these new opportunities for TMH will be presented at an earlier stage than would otherwise be the case. We believe that there is an excellent fit between our organisations and very much look forward to working with Catalent. We are confident that this collaboration will provide the basis for TMH to fully exploit the simplicity and versatility of our proprietary autoinjector systems, enabling us to build on earlier successes in licensing these technologies and further enhancing our profile and financial performance."
Publish Date: Thursday, November 08, 2007